Association Between Plasma Homocysteine Levels and Subclinical Hypothyroidism in Adult Subjects: A Meta-Analysis

Abstract

Increased plasma homocysteine (Hcy) levels have been widely documented in patients with overt hypothyroidism; however, the significance of Hcy level changes in patients with subclinical hypothyroidism (SCH) remains controversial. The aim of this meta-analysis was to determine the Hcy status in patients with SCH compared with euthyroid subjects. We searched PubMed, Embase, and Cochrane Library databases prior to December 2019 to identify eligible studies and assessed the quality of selected studies using the Newcastle-Ottawa Quality Assessment Scale. Publication bias was evaluated by Begg’s test and Egger’s test. Meta-regression analysis was conducted to investigate the source of heterogeneity. A likely source of heterogeneity was the year of the study. All statistical analyses were performed with RevMan 5.3 and Stata 12.0 software. Our meta-analysis of twelve observational studies with 684 patients showed that those with SCH aged between 18 and 65 years old were associated with a slightly increased plasma Hcy level compared with euthyroid controls. The pooled result of the weighted mean difference (WMD) of increased tHcy levels was 1.16 μmol/l (95% CI: 0.51, 1.82; p=0.0005). The Hcy level in patients with SCH aged between 18 and 65 years old is significantly increased compared to euthyroid controls.

Key words

Subclinical hypothyroidism - hyperhomocysteinemia - cardiovascular disease - meta-analysis

Publikationsverlauf

Eingereicht: 08. Mai 2020

Angenommen: 04. Juni 2020

Artikel online veröffentlicht:
06. Juli 2020

• References

• 1 Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: A review. JAMA 2019; 322: 153-160
• 2 Delitala AP, Scuteri A, Maioli M. et al. Subclinical hypothyroidism and cardiovascular risk factors. Minerva Med 2019; 110: 530-545
• 3 Sert A, Pirgon O, Aypar E. et al. Subclinical hypothyroidism as a risk factor for the development of cardiovascular disease in obese adolescents with nonalcoholic fatty liver disease. Pediatr Cardiol 2013; 34: 1166-1174
• 4 Asvold BO, Bjøro T, Platou C. et al. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway. Clin Endocrinol (Oxf) 2012; 77: 911-917
• 5 Gao N, Zhang W, Zhang YZ. et al. Carotid intima-media thickness in patients with subclinical hypothyroidism: A meta-analysis. Atherosclerosis 2013; 227: 18-25
• 6 Rosário PWS, Calsolari MR. Subclinical hypothyroidism with TSH>7 mIU/l and ≤10 mIU/l and coronary artery disease. Horm Metab Res 2020; 52: 85-88
• 7 Jabbar A, Pingitore A, Pearce SH. et al. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol 2017; 14: 39-55
• 8 Ganguly P, Alam SF. Role of homocysteine in the development of cardiovascular disease. Nutr J 2015; 14: 6
• 9 Orzechowska-Pawilojc A, Sworczak K, Lewczuk A. et al. Homocysteine, folate and cobalamin levels in hypothyroid women before and after treatment. Endocr J 2007; 54: 471-476
• 10 Yang N, Yao Z, Miao L. et al. Novel clinical evidence of an Association between homocysteine and insulin resistance in patients with hypothyroidism or subclinical hypothyroidism. PLoS One 2015; 10: e0125922
• 11 Adrees M, Gibney J, El-Saeity N. et al. Effects of 18 months of L-T4 replacement in women with subclinical hypothyroidism. Clin Endocrinol (Oxf) 2009; 71: 298-303
• 12 Gunduz M, Gunduz E, Kircelli F. et al. Role of surrogate markers of atherosclerosis in clinical and subclinical thyroidism. Int J Endocrinol 2012; 109797
• 13 Ebrahimpour A, Vaghari-Tabari M, Qujeq D. et al. Direct correlation between serum homocysteine level and insulin resistance index in patients with subclinical hypothyroidism: Does subclinical hypothyroidism increase the risk of diabetes and cardiovascular disease together?. Diabetes Metab Syndr 2018; 12: 863-867
• 14 Dong X, Yao Z, Hu Y. et al. Potential harmful correlation between homocysteine and low-density lipoprotein cholesterol in patients with hypothyroidism. Medicine (Baltimore) 2016; 95: e4291
• 15 Vayá A, Giménez C, Sarnago A. et al. Subclinical hypothyroidism and cardiovascular risk. Clin Hemorheol Microcirc 2014; 58: 1-7
• 16 Cakal B, Cakal E, Demirbaş B. et al. Homocysteine and fibrinogen changes with L-thyroxine in subclinical hypothyroid patients. J Korean Med Sci 2007; 22: 431-435
• 17 Luboshitzky R, Aviv A, Herer P. et al. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2002; 12: 421-425
• 18 Aldasouqi S, Nkansa-Dwamena D, Bokhari S. et al. Is subclinical hypothyroidism associated with hyperhomocysteinemia?. Endocr Pract 2004; 10: 399-403
• 19 Luboshitzky R, Herer P. Cardiovascular risk factors in middle-aged women with subclinical hypothyroidism. Neuro Endocrinol Lett 2004; 25: 262-266
• 20 Erdal M, Sahin M, Saglam K. et al. Increased serum chitotriosidase activity following restoration of euthyroidism in patients with subclinical hypothyroidism. Intern Med 2008; 47: 1309-1314
• 21 Turhan S, Sezer S, Erden G. et al. Plasma homocysteine concentrations and serum lipid profile as atherosclerotic risk factors in subclinical hypothyroidism. Ann Saudi Med 2008; 28: 96-101
• 22 Stroup DF, Berlin JA, Morton SC. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012
• 23 Higgins JP, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
• 24 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
• 25 Djuric D, Jakovljevic V, Zivkovic V. et al. Homocysteine and homocysteine-related compounds: An overview of the roles in the pathology of the cardiovascular and nervous systems. Can J Physiol Pharmacol 2018; 96: 991-1003
• 26 Zhu M, Mao M, Lou X. Elevated homocysteine level and prognosis in patients with acute coronary syndrome: A meta-analysis. Biomarkers 2019; 24: 309-316
• 27 Chrysant SG, Chrysant GS. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review. Expert Rev Cardiovasc Ther 2018; 16: 559-565
• 28 Collet TH, Gussekloo J, Bauer DC. et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172: 799-809
• 29 Chaker L, Baumgartner C, den Elzen WP. et al. Subclinical hypothyroidism and the risk of stroke events and fatal stroke: An individual participant data analysis. J Clin Endocrinol Metab 2015; 100: 2181-2191
• 30 Pasqualetti G, Tognini S, Polini A. et al. Is subclinical hypothyroidism a cardiovascular risk factor in the elderly?. J Clin Endocrinol Metab 2013; 98: 2256-2266
• 31 Moll S, Varga EA. Homocysteine and MTHFR Mutations. Circulation 2015; 132: e6-e9
• 32 Williams KT, Schalinske KL. Homocysteine metabolism and its relation to health and disease. Biofactors 2010; 36: 19-24
• 33 Bamashmoos SA, Al-Nuzaily MA, Al-Meeri AM. et al. Relationship between total homocysteine, total cholesterol and creatinine levels in overt hypothyroid patients. Springerplus 2013; 2: 423
• 34 Zhang W, Tian LM, Han Y. et al. Presence of thyrotropin receptor in hepatocytes: Not a case of illegitimate transcription. J Cell Mol Med 2009; 13: 4636-4642
• 35 Li WX, Lv WW, Dai SX. et al. Joint associations of folate, homocysteine and MTHFR, MTR and MTRR gene polymorphisms with dyslipidemia in a Chinese hypertensive population: A cross-sectional study. Lipids Health Dis 2015; 14: 101